Unique clinicopathological features of metaplastic breast carcinoma compared with invasive ductal carcinoma and poor prognostic indicators

详细信息    查看全文

• 作者：Yanni Song (7)
  Xiaolong Liu (6) (7)
  Guoqiang Zhang (7)
  Hongtao Song (6)
  Yanlv Ren (7)
  Xiaoguang He (6) (7)
  Yanbo Wang (7)
  Jinfeng Zhang (7)
  Youxue Zhang (7)
  Shanshan Sun (7)
  Xiaoshuan Liang (7)
  Qian Sun (7)
  Da Pang (7) (7)
  
• 关键词：Breast cancer ; Clinical outcomes ; Metaplasia ; Pathologic features ; Prognosis
• 刊名：World Journal of Surgical Oncology
• 出版年：2013
• 出版时间：December 2013
• 年：2013
• 卷：11
• 期：1
• 全文大小：305KB
• 参考文献：1. Tavassoli FA: Classification of metaplastic carcinomas of the breast. / Pathol Annu 1992, 27:89-19.
  2. Bocker W: WHO classification of breast tumors and tumors of the female genital organs: patholog and genetics. / Verh Dtsch Ges Pathol 2002, 86:116-19.
  3. Chao TC, Wang CS, Chen SC, Chen MF: Metaplastic carcinomas of the breast. / J Surg Oncol 1999, 71:220-25. CrossRef
  4. Pezzi CM, Patel-Parekh L, Cole K, Franko J, Klimberg VS, Bland K: Characteristics and treatment of metaplastic breast cancer: analysis of 892 cases from the National Cancer Data Base. / Ann Surg Oncol 2007, 14:166-73. CrossRef
  5. Jung SY, Kim HY, Nam BH, Min SY, Lee SJ, Park C, Kwon Y, Kim EA, Ko KL, Shin KH: Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer. / Breast Cancer Res Treat 2010, 120:627-37. CrossRef
  6. Rakha EA, Ellis IO: Triple-negative/basal-like breast cancer: review. / Pathology 2009, 41:40-7. CrossRef
  7. Beatty JD, Atwood M, Tickman R, Reiner M: Metaplastic breast cancer: clinical significance. / Am J Surg 2006, 191:657-64. CrossRef
  8. Korsching E, Jeffrey SS, Meinerz W, Decker T, Boecker W, Buerger H: Basal carcinoma of the breast revisited: an old entity with new interpretations. / J Clin Pathol 2008, 61:553-60. CrossRef
  9. Barnes PJ, Boutilier R, Chiasson D, Rayson D: Metaplastic breast carcinoma: clinical-pathologic characteristics and HER2/neu expression. / Breast Cancer Res Treat 2005, 91:173-78. CrossRef
  10. Hennessy BT, Krishnamurthy S, Giordano S, Buchholz TA, Kau SW, Duan Z, Valero V, Hortobagyi GN: Squamous cell carcinoma of the breast. / J Clin Oncol 2005, 23:7827-835. CrossRef
  11. Gibson GR, Qian D, Ku JK, Lai LL: Metaplastic breast cancer: clinical features and outcomes. / Am Surg 2005, 71:725-30.
  12. Park HS, Park S, Kim JH, Lee JH, Choi SY, Park BW, Lee KS: Clinicopathologic features and outcomes of metaplastic breast carcinoma: comparison with invasive ductal carcinoma of the breast. / Yonsei Med J 2010, 51:864-69. CrossRef
  13. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. / J Clin Oncol 2010, 28:2784-795. CrossRef
  14. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. / J Clin Oncol 2007, 25:118-45. CrossRef
  15. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. / J Natl Cancer Inst 2009, 101:736-50. CrossRef
  16. Bellino R, Arisio R, D’Addato F, Attini R, Durando A, Danese S, Bertone E, Grio R, Massobrio M: Metaplastic breast carcinoma: pathology and clinical outcome. / Anticancer Res 2003, 23:669-73.
  17. Bae SY, Lee SK, Koo MY, Hur SM, Choi MY, Cho DH, Kim S, Choe JH, Lee JE, Kim TH, Kim JS: The prognoses of metaplastic breast cancer patients compared to those of triple-negative breast cancer patients. / Breast Cancer Res Treat 2011, 126:471-78. CrossRef
  18. Luini A, Aguilar M, Gatti G, Fasani R, Botteri E, Brito JA, Maisonneuve P, Vento AR, Viale G: Metaplastic carcinoma of the breast, an unusual disease with worse prognosis: the experience of the European Institute of Oncology and review of the literature. / Breast Cancer Res Treat 2007, 101:349-53. CrossRef
  19. Wargotz ES, Norris HJ: Metaplastic carcinomas of the breast. I. Matrix-producing carcinoma. / Hum Pathol 1989, 20:628-35. CrossRef
  20. Wargotz ES, Deos PH, Norris HJ: Metaplastic carcinomas of the breast. II. Spindle cell carcinoma. / Hum Pathol 1989, 20:732-40. CrossRef
  21. Wargotz ES, Norris HJ: Metaplastic carcinomas of the breast. III. Carcinosarcoma. / Cancer 1989, 64:1490-499. CrossRef
  22. Mourad WA: Book review: Rosen's breast pathology. / Ann Saudi Med 1998, 18:278.
  23. Khan HN, Wyld L, Dunne B, Lee AH, Pinder SE, Evans AJ, Roertson JF: Spindle cell carcinoma of the breast: a case series of a rare histological subtype. / Eur J Surg Oncol 2003, 29:600-03. CrossRef
  24. Lien HC, Hsiao YH, Lin YS, Yao YT, Juan HF, Kuo WH, Hung MC, Chang KJ, Hsieh FJ: Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial-mesenchymal transition. / Oncogene 2007, 26:7859-871. CrossRef
  25. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee JS, Sahin A, Agarwal R, Joy L, Liu W, Stivers D, Baggerly K: Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. / Cancer Res 2009, 69:4116-124. CrossRef
  
• 作者单位：Yanni Song (7)
  Xiaolong Liu (6) (7)
  Guoqiang Zhang (7)
  Hongtao Song (6)
  Yanlv Ren (7)
  Xiaoguang He (6) (7)
  Yanbo Wang (7)
  Jinfeng Zhang (7)
  Youxue Zhang (7)
  Shanshan Sun (7)
  Xiaoshuan Liang (7)
  Qian Sun (7)
  Da Pang (7) (7)
  
  7. Heilongjiang Institute for Cancer Research, 6 Baojian Road, Harbin, 150040, China
  6. Department of Tumor Surgery, Heilongjiang Province Land Reclamation Headquarters General Hospital, 235 Hashuang Road, Harbin, 150088, China
  

文摘

Background Metaplastic breast carcinoma is a rare aggressive malignant neoplasm. The purposes of this study are to review the pathologic features and clinical outcomes of metaplastic breast carcinoma compared to invasive ductal carcinoma and to evaluate the prognosis of metaplastic breast carcinoma. Methods The cases of 55 patients with metaplastic breast carcinomapresenting between 1991 and 2006 were analyzed and compared to the cases of 767 age-matched patients with invasive ductal carcinoma from the same time period. Results The group of patients with metaplastic breast carcinoma presented with a larger tumor size, lower lymph node involvement, higher percentage of triple-negative (estrogen receptor-, progesterone receptor- and human epidermal growth factor receptor-2-negative) cases, and Ki-67 over-expression compared with the group of patients with invasive ductal carcinoma and triple-negative invasive ductal carcinomas. Patients in the metaplastic breast carcinoma group tended to have more local (often chest wall) recurrences (P = 0.038) and distant (often lung) metastases (P = 0.001) than those in the invasive ductal carcinomas group. The prognosis of metaplastic breast carcinoma was poorer than that of invasive ductal carcinoma and triple-negative invasive ductal carcinomas; the 5-year overall survival rate was 54.5% in metaplastic breast carcinoma versus 85.1% in invasive ductal carcinoma, and 73.3% in triple-negative invasive ductal carcinomas (P <0.001). The 5-year disease-free survival rate was 45.5% in metaplastic breast carcinoma versus 71.2% in invasive ductal carcinoma, and 60.3% in triple-negative invasive ductal carcinomas (P <0.001). Multivariate analysis revealed tumor size larger than 5.0 cm, lymph node involvement and Ki-67?4% were significantly related to 5-year overall survival (P = 0.010; P = 0.010; P = 0.035) and 5-year disease-free survival (P = 0.020; P = 0.018; P = 0.049). Conclusions Metaplastic breast carcinoma shows a poorer prognosis than both invasive ductal carcinoma and triple-negative invasive ductal carcinomas. Tumor size larger than 5.0 cm, lymph node involvement and Ki-67 ?4% indicate a poor prognosis in patients with metaplastic breast carcinoma.